key: cord-0913522-nkufkyox
authors: Wussow, Felix; Kha, Mindy; Faircloth, Katelyn; Nguyen, Vu H.; Iniguez, Angelina; Martinez, Joy; Park, Yoonsuh; Nguyen, Jenny; Kar, Swagata; Andersen, Hanne; Lewis, Mark G.; Chiuppesi, Flavia; Diamond, Don J.
title: COH04S1 and Beta Sequence Modified Vaccine Protect Hamsters From SARS-CoV-2 Variants
date: 2022-05-23
journal: iScience
DOI: 10.1016/j.isci.2022.104457
sha: f0cfd2a874f1bc9734be31fd752e61a6ea78c267
doc_id: 913522
cord_uid: nkufkyox

COVID-19 vaccine efficacy is threatened by emerging SARS-CoV-2 variants of concern (VOC) with the capacity to evade protective neutralizing antibody responses. We recently developed clinical vaccine candidate COH04S1, a synthetic modified vaccinia Ankara vector (sMVA) co-expressing spike and nucleocapsid antigens based on the Wuhan-Hu-1 reference strain that showed potent efficacy to protect against ancestral SARS-CoV-2 in Syrian hamsters and non-human primates and was safe and immunogenic in healthy volunteers. Here, we demonstrate that intramuscular immunization of Syrian hamsters with COH04S1 and an analogous Beta variant-adapted vaccine candidate (COH04S351) elicits potent cross-reactive antibody responses and protects against weight loss, lower respiratory tract infection, and lung pathology following challenge with major SARS-CoV-2 VOC, including Beta and the highly contagious Delta variant. These results demonstrate efficacy of COH04S1 and a variant-adapted vaccine analogue to confer cross-protective immunity against SARS-CoV-2 and its emerging VOC, supporting clinical investigation of these sMVA-based COVID-19 vaccine candidates.

Immediately after the outbreak of the COVID-19 pandemic (Zhou et al., 2020 , Zhu et al., 2020 , 27 several severe acute respiratory syndrome virus 2 (SARS-CoV-2) variants of concern (VOC) have 28 emerged with the capacity to spread more effectively and to evade neutralizing antibodies (NAb) 29 stimulated through natural infection or vaccination (Tegally et 

Compared to controls, COH04S1-and COH04S351-vaccinated hamsters showed significantly 155 reduced lung histopathology at day 3 and 10 following challenge with the ancestral virus or the 156 two variant viruses (Figure 3A-C and Figure S1 ). Lung pathology in COH04S1-and COH04S351-157 vaccinated hamsters following challenge with the ancestral virus or the two variant viruses was in 158 most cases either limited or undetectable, with no significant differences between the two vaccine 159

groups. In addition, while all control animals showed high-grade bronchioalveolar hyperplasia (i.e. ). When vaccine immunogenicity and protective efficacy were stratified by sex we observed 173 minor differences between female and male vaccinated hamsters ( Figure S4) . A significant body 174 weight reduction in male versus female animals was observed after five days in control hamsters 175 following challenge with the Beta and Delta VOC, which appears consistent with the known 176 differential susceptibility of female and male hamsters to SARS-CoV-2 (Yuan et al., 2021) . In 177 addition, female COH04S351-vaccinated hamsters showed significantly improved body weight 178 than male COH04S351-vaccinated hamsters at late time points following challenge with Delta. 179

Immune responses and protection against lung viral loads and lung pathology appeared generally 180 similar between males and female hamsters, although male COH04S351-vaccinated hamsters 181 showed significant higher Delta-specific NAb responses than female COH04S351-vaccinated 182 hamsters, while lung viral loads in male COH04S1-vaccinated hamsters were significantly lower 183 than those in female COH04S1-vaccinated hamsters, indicating a minor strain-specific vaccine 184 impact depending on sex. These results demonstrate that COH04S1 and COH04S351 afford 185 potent efficacy to protect Syrian hamsters from lung pathology following challenge with ancestral 186 SARS-CoV-2 and SARS-CoV-2 Beta and Delta variants. 187

The ongoing emergence of SARS-CoV-2 VOC jeopardizes the efficacy of approved COVID-19 189 vaccines that were antigenically designed based on the original Wuhan-Hu-1 reference isolate. It 190 is therefore of critical importance to address whether Wuhan-Hu-1-specific vaccines have the 191 capacity to protect against major SARS-CoV-2 VOC as much as it is important to assess whether 

A major limitation of the study was that we did not independently address the contribution of the 278 S and N antigens to the protective efficacy observed with COH04S1 and COH04S351, nor did we We would like to thank Angela Wong and Christina Ulloa for helping with laboratory logistics and 306 secretarial support. We would like to acknowledge the Bioqual team for their technical support. 307

We gratefully acknowledge City of Hope's unique internal funding mechanism of selected 308 scientific discoveries, enabling preclinical and clinical development to speedily advance products 309 toward commercialization, such as COH04S1. The following reagent was deposited by the 310 

While unknown whether publication of this report will aid in receiving grants and contracts, it is 319 possible that this publication will be of benefit to City of Hope (COH). COH had no role in the 320 conceptualization, design, data collection, analysis, decision to publish, or preparation of the represent median values and 95% CI, respectively. Peaks of weight loss in each group were 367 compared using one-way ANOVA followed by Tukey's multiple comparison test. Only animals 368 with endpoint at day 10 were included. *=0.05 < p <0.01, **=0.01 < p < 0.001, 369 ***=0.001 < p < 0.0001, ****=p < 0.0001. 370

CoV-2 sub-genomic RNA (sgRNA) copies were quantified by qPCR in lung tissue (A-C) and nasal 373 turbinates (D-F) of COH04S1 and COH04S351 vaccine and control groups at days 3 and 10 374

following challenge with ancestral SARS-CoV-2 (A, D) or SARS-COV-2 Beta (B, E) and Delta (C, 375 F) variants. Lines indicate median RNA copies. One-way ANOVA followed by Tukey's multiple 376 comparison test was used. *=0.05 < p <0.01, **=0.01 < p < 0.001, ***=0.001 < p < 0.0001. 377 

Further information and requests for resources and reagents should be directed to the lead 393 contact, Don J. Diamond (ddiamond@coh.org). 394

All requests for resources and reagents should be directed to the Lead Contact author. All 396 reagents will be made available on request after completion of a Materials Transfer Agreement. 397

All data supporting the findings of this study are available within the paper and are available from 399 the corresponding author upon request. This paper does not include original code. Any additional 400 information required to reanalyze the data reported in this paper is available from the lead contact 401 upon request. 402

COH04S1 is a double-plaque purified virus isolate derived from the previously described sMVA-405 were incubated in 96-well plates with 30 PFU of SARS-CoV-2 ancestral, beta or delta strains for 461 1 hour at 37°C. The serum/virus mixture was transferred to Vero-E6 cells and incubated for 1 462 hour at 37°C. After that, 1 ml of 0.5% methylcellulose media was added to each well and plates 463

were incubated at 37°C for three days. Plates were washed, and cells were fixed with methanol. 464

Crystal violet staining was performed, and plaques were recorded. IC50 titers were calculated as 465 the serum dilution that gave a 50% reduction in viral plaques in comparison to control wells. 

Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in 496 Transplant Recipients: A Phase 2, Randomized Clinical Trial

Covid-19 Vaccine E

Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic 589 antibody response in the lung

Multiple SARS-CoV-2 variants escape neutralization by 593 vaccine-induced humoral immunity

Clinical development of Modified Vaccinia virus Ankara vaccines

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease 600 and Unexposed Individuals

CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and 605 emerging B.1.351 SARS-CoV-2

Neutralizing antibody levels are highly 615 predictive of immune protection from symptomatic SARS-CoV-2 infection

MVA vaccine encoding CMV antigens safely induces durable expansion 620 of CMV-specific T cells in healthy adults

One or two injections 622 of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower 623 respiratory tract infection

627 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Covid-19 Vaccine against the B.1.351 Variant

Correlates of protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody 663 neutralization

Booster vaccines protect hamsters with waning 672 immunity from Delta VOC infection, disease, and transmission

Efficacy of a Fourth 676 Dose of Covid-19 mRNA Vaccine against Omicron

Safety and 682 Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness 694 against Death from the Delta Variant

Pathogenesis and transmission of 706 SARS-CoV-2 in golden hamsters

Nonreplicating vaccinia vector efficiently expresses recombinant genes

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS

CoV-2 Delta variant in Qatar

Ad26 vaccine 731 protects against SARS-CoV-2 severe clinical disease in hamsters

Vaccines-A Comparison of Vaccine Candidate Genes in Roborovski Dwarf Hamsters. Viruses

Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current 737 Perspectives for Vaccine Development

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine 751 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil

Human cytomegalovirus vaccine based on the envelope gH/gL pentamer 766 complex

A vaccine based on the rhesus cytomegalovirus UL128 complex induces 769 broadly neutralizing antibodies in rhesus macaques

Evasion of Type I Interferon by SARS-CoV-2

A single dose of 777 recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge

Cell Surface SARS-CoV-2 Nucleocapsid Protein 780 Modulates Innate and Adaptive Immunity

Gender associates with both susceptibility to infection 791 and pathogenesis of SARS-CoV-2 in Syrian hamster

Complete regression of cutaneous metastases with 794 systemic immune response in a patient with triple negative breast cancer receiving p53MVA 795 vaccine with pembrolizumab

CoV-2 variant B.1.351 from natural and vaccine-induced sera

A pneumonia outbreak associated with a new coronavirus of probable bat 808 origin

CHINA NOVEL CORONAVIRUS, 811 I. & RESEARCH, T. 2020. A Novel Coronavirus from Patients with Pneumonia in China